Patents by Inventor Helle Woeldike

Helle Woeldike has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGF21 ANALOGUES AND DERIVATIVES
    Publication number: 20130252884
    Abstract: Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described.
    Type: Application
    Filed: June 6, 2011
    Publication date: September 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Patrick William Garibay, Helle Woeldike, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Tina Moeller Tagmose
  • IL-21 derivatives and variants
    Patent number: 8450459
    Abstract: The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: May 28, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Christine Bruun Schiødt, Helle Wöldike, Florencio Zaragoza Dörwald, Anne Worsaae
  • FGF21 ANALOGUES AND DERIVATIVES
    Publication number: 20120035099
    Abstract: Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process.
    Type: Application
    Filed: June 6, 2011
    Publication date: February 9, 2012
    Applicant: NOVO NORDISK A/S
    Inventors: WILLIAM PATRICK GARIBAY, HELLE WÖLDIKE, XUJIA ZHANG, HENNING THØGERSEN, PETER KRESTEN NIELSEN, BIRGITTE ANDERSEN, JISHU WANG, KRISTIAN SASS BAK-JENSEN, TINA MØLLER TAGMOSE
  • FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use
    Publication number: 20100216715
    Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.
    Type: Application
    Filed: January 22, 2010
    Publication date: August 26, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Tina Møller Tagmose, Patrick William Garibay, Bírgítte Andersen, Jishu Wang, Kílían Waldemar Conde-Frieboes, Kristían Sass Bak-Jensen, Henning Thøgersen, Helle Wöldike, Peter Kresten Nielsen, Rita Slaaby, Xujia Zhang, Birgit Wieczorek
  • Method for the production of factor VII
    Patent number: 6329176
    Abstract: Disclosed is a method for high efficiency release of recombinant proteins in eukaryotic cells and more specifically, for enhancing the secretion of Factor VII by co-expression of kex2 endoprotease with FVII in cells of mammalian origin.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: December 11, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Helle Wöldike, Finn Wiberg, Lars Søegaard Nielsen